You have full text access to this OnlineOpen article

The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects

  1. Tae H. Han PhD1,2,*,
  2. Rebecca L. Blanchard PhD1,
  3. John Palcza MS1,
  4. Ashley Martucci BS1,
  5. Cynthia M. Miller-Stein BS1,
  6. Maria Gutierrez MD3,
  7. Deborah Panebianco MS1,
  8. Ronda K. Rippley PhD1,
  9. Christopher Lines PhD1,
  10. M. Gail Murphy MD1

Article first published online: 22 NOV 2010

DOI: 10.1111/j.1753-5174.2010.00031.x

Issue

Archives of Drug Information

Archives of Drug Information

Volume 3, Issue 4, pages 55–62, December 2010

Additional Information

How to Cite

Han, T. H., Blanchard, R. L., Palcza, J., Martucci, A., Miller-Stein, C. M., Gutierrez, M., Panebianco, D., Rippley, R. K., Lines, C. and Murphy, M. G. (2010), The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects. Archives of Drug Information, 3: 55–62. doi: 10.1111/j.1753-5174.2010.00031.x

Author Information

  1. 1

    Merck & Co., Inc., Whitehouse Station, NJ, USA

  2. 2

    Seattle Genetics Inc, Bothell, WA, USA

  3. 3

    Comprehensive Phase One, Miramar FL, USA

*Tae Han, PhD, Seattle Genetics, Inc. 21823—30th Drive S.E., Bothell, WA, 98021, USA. Tel: 425-527-4928; Fax: 425-527-4001; E-mail: than@seagen.com

  1. Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

Publication History

  1. Issue published online: 7 DEC 2010
  2. Article first published online: 22 NOV 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (257K)

References

  • 1
    Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193–210.
    Direct Link:
  • 2
    Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999;15:813–8.
  • 3
    Durham PL. Inhibition of calcitonin gene-related peptide function: A promising strategy for treating migraine. Headache 2008;48:1269–75.
    Direct Link:
  • 4
    Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache 2008;48:1259–68.
    Direct Link:
  • 5
    Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414–25.
    Direct Link:
  • 6
    Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: Discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564–7.
  • 7
    Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-( 2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416–21.
  • 8
    Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304–12.
  • 9
    Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115–23.
  • 10
    Connor KM, Shapiro RE, Diener H-C, Lucas S, Kost J, Fan X, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73:970–7.
  • 11
    Roller S, Cui D, Laspina C, Miller-Stein C, Rowe J, Wong B, et al. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica 2009;39:33–45.
  • 12
    Han TH, Blanchard RL, Palcza J, McCrea JB, Laethem T, Willson KJ, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 2010;50:1367–76.
  • 13
    Xu Y, Willson KW, Anderson MDG, Miller-Stein CM, Woolf EJ. Elimination of diastereomer interference to determine Telcagepant (MK-0974) in human plasma using on-line turbulent-flow technology and off-line solid-phase extraction coupled with liquid chromatography/tandem mass spectrometry. J Chromatogr B 2009;877:1634–42.
View Full Article (HTML) Get PDF (257K)